Introduction {#S1}
============

Antimicrobial resistance has become one of the most challenging problems for public health and results in 700,000 deaths annually ([@B52]). Antibiotic misuse has led to the spread of antibiotic resistance genes (ARGs) in humans, food animals, pets, songbirds, water, and soil and even agricultural plants, and this represents a significant threat to public health security ([@B13]; [@B25]; [@B2]; [@B15]; [@B21]; [@B67]; [@B75]). However, novel ARGs have emerged that encode resistance to carbapenems (*bla*~NDM~, *bla*~IMP~, *bla*~VIM~, and *bla*~KPC~) ([@B55]) colistin (*mcr-1* to *9*) and tigecycline (*tet*X3 and *tet*X4) ([@B12]; [@B26]; [@B78]). The current limited development of novel drugs and substitutes makes the use of ARGs monitoring even more important to develop comprehensive and integrative measures for antimicrobial resistance.

Over the past two decades, there has been a significant number of infections caused by bacteria expressing extended-spectrum-β-lactamase (ESBL) and carbapenemases ([@B39]). In particular, ESBL isolates have been found in humans ([@B57]), animals, the environment (water and soil) ([@B64]), meat and even vegetables ([@B81]). ESBL are becoming more common because this phenotype is being selected for by the use and exposure to β-lactams, especially the cephalosporins. This has generated a vicious cycle of drug resistance and decreased therapeutic effects. The increasing use of cephalosporin has been linked to *Escherichia coli* infections in pigs ([@B24]) and a high frequency of ESBL-producing *E. coli* was directly linked with a high consumption of third- or fourth- cephalosporins ([@B3]).

One area that has not been thoroughly investigated is ARG presence in companion animals. This group comes in intimate contact with humans and pet contact can lead to bacterial spread to humans ([@B38]). In particular, *E. coli* is a common pathogenic agent isolated from pets ([@B44]) and is often present in dogs and cats with urinary tract infections (UTIs), pyometra and respiratory tract infections ([@B28]; [@B50]). Multidrug resistance (MDR) *E. coli* isolates have emerged in companion animals in the United States and Europe ([@B49]), but data for China is lacking.

Here, we explored the effects of antibiotic dose on resistance phenotypes in pet bacterial isolates over a 6-year period. The aim of this study was to investigate the dissemination of ESBL-producing multidrug-resistant pathogens in diseased pets and the correlation between resistance rates and consumption of β-lactam antibiotics.

Materials and Methods {#S2}
=====================

Samples and Identification of Bacterial Isolates {#S2.SS1}
------------------------------------------------

Animal samples were collected at the Veterinary Teaching Hospital of China Agricultural University (VTH-CAU), between January 2012 and June 2017. This study was approved by the China Agricultural University Animal Ethics Committee and the approval document (No. AW08104102-2) (see [Supplementary Information](#TS1){ref-type="supplementary-material"}). We collected 1886 samples from dogs (1565) and cats (321) and where some samples were gathered from different infections in the same pet. All samples consisted of urine (UTI) samples (1398, 74.1%) and samples from pyoderma (125, 6.7%), ear swabs (6.1%), effusions (115, 6.1%) and other specimens (132, 7.0%), which included pus from the uterus and soft tissue infections and several trachea lavage fluids.

Bacterial strains were recovered using blood agar and MacConkey agar plates that were incubated at 37°C for 24 h and single pink colonies were collected from each isolation plate. Subsequently, the DNA of individual clones was extracted by Fast Pure Bacteria DNA Isolation Mini Kit (Vazyme Biotech, Nanjing, China) and used as templates for PCR. PCR amplification of the 16S rDNA gene were performed for all isolates as previously described ([@B10]), and amplicons were sequenced to confirm bacterial genus using the BLAST algorithm^[1](#footnote1){ref-type="fn"}^.

Antimicrobial Susceptibility Testing {#S2.SS2}
------------------------------------

Antimicrobial susceptibility of isolates was performed using the broth microdilution method according to Clinical and Laboratory Standards Institute guidelines ([@B16]). The breakpoints for other antimicrobials used the CLSI (M100-S25 or Vet01-A4/Vet01-S2) and EUCAST ([@B17]; [@B18]), where the breakpoints (R) for tigecycline, orbifloxacin, enrofloxacin, and marbofloxacin were recommended as ≥0.5, ≥4, ≥4, and ≥8 μg/ml, respectively. The screening panel consisted of 17 antibiotics that included ampicillin, cefazolin, cefotaxime, ceftriaxone, meropenem, amoxicillin-clavulanic acid, aztreonam, ciprofloxacin, enrofloxacin, marbofloxacin, orbifloxacin, chloramphenicol, amikacin, gentamicin, doxycycline, colistin, and tigecycline. Isolates with resistance to three or more categories of antimicrobial agents were classified as MDR ([@B41]). *E. coli* ATCC 25922 was used as the quality control strain. Resistance was categorized according to Standardized International Terminology and our 17 test antibiotics were contained within nine categories ([@B41]).

Survey of Antimicrobial Drug Usage at the VTH-CAU {#S2.SS3}
-------------------------------------------------

Antibiotic usage at VTH-CAU was recorded between January 2014 and September 2017 to correlate antibiotic usage and the resistance of *E. coli* isolates for each study animal.

ARG Detection {#S2.SS4}
-------------

Screening of *E. coli* isolates for ARG types was conducted using PCR for each isolate depending on the antibiotic resistance phenotype. The ARGs we examined were (1) carbapenemase genes *bla*~NDM~, *bla*~IMP~ *bla*~KPC~, *bla*~VIM~, *bla*~OXA~, *bla*~AIM~, *bla*~BIC~, *bla*~DIM~, *bla*~GIM~, *bla*~SIM~, and *bla*~SPM~ including *bla*~NDM~ and *bla*~CTX--M~ subtyping ([@B58]), (2) β-lactamase genes *bla*~SHV~, *bla*~TEM~, and *bla*~CTX--M~ ([@B14]), (3) plasmid-mediated AmpC β-lactamase genes *bla*~MOX~, *bla*~CMY~, *bla*~LAT~, *bla*~DHA~, *bla*~ACC~, *bla*~MIR~, *bla*~ACT~, and *bla*~FOX~ ([@B56]), (4) colistin resistance genes *mcr-1*-*8* ([@B61]; [@B77]; [@B82]; [@B12]), and (5) plasmid-mediated quinolone resistance (PMQR) genes *qnrA, qnrB* and *qnrS* including whether the *gyr*A and *par*C genes in the quinolone resistance determining region (QRDR) were mutated ([@B31]; [@B32]; [@B53]). PCR primers used for screening are shown in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}. All PCR amplicons were sequenced to confirm gene identity.

Transconjugation Assays and Whole Genome Sequencing {#S2.SS5}
---------------------------------------------------

Conjugation assays were performed between clinical isolates and *E. coli* J53 to evaluate whether *bla*~NDM~ and *mcr-1* were mobilizable. Transconjugants were selected on MacConkey agar containing 100 mg/L sodium azide and 1 mg/L meropenem or colistin. Presumptive transconjugants were identified using PCR screening for *bla*~NDM~ and *mcr-1*.

Transconjugant DNA was extracted and used for whole genome sequencing (WGS). A library of 250-bp paired-end was constructed by using a NEXT Ultra DNA Library Prep kit (New England Biolabs, Beverley, MA, United States) and sequenced using an Illumina HiSeq 2500 system at Bionova Biotech (Beijing, China). Raw data was *de novo* assembled using the SPAdes algorithm v.3.10.0. ARGs and plasmid incompatibility groups were analyzed using ResFinder v.3.2^[2](#footnote2){ref-type="fn"}^, RASTtk v.2.0^[3](#footnote3){ref-type="fn"}^ and PlasmidFinder 2.1^[4](#footnote4){ref-type="fn"}^, respectively.

PFGE and MLST Typing of *E. coli* Strains {#S2.SS6}
-----------------------------------------

The clonal relatedness of *bla*~CTX--M~ positive was determined using pulsed-field gel electrophoresis (PFGE) typing conducted as previously described ([@B72]). PFGE patterns were visually inspected and gel images were analyzed using InfoQuest FP software (Biorad, Hercules, CA, United States). Group analysis of PFGE profiles was performed using the Dice coefficient and the unweighted pair group method with arithmetic means. Simultaneously, multilocus sequence typing (MLST) analysis was conducted using the following *E. coli* gene set: *recA, adk, fumC, icd, mdh, purA*, and *gyrB.* The results were interpreted using the MLST database^[5](#footnote5){ref-type="fn"}^. Sequence types (STs) of 131 clades in *E. coli* isolates were also screened using multiplex conventional PCR assays as previously described ([@B46]).

Statistical Analysis {#S2.SS7}
--------------------

Tests of statistical significance was determined using Fisher's exact test with Yates continuity correction in GraphPad Prism 6 (San Diego, CA, United States) and the level of significance was set at *P* \< 0.05. All figures were designed by ggplot2^[6](#footnote6){ref-type="fn"}^ and GraphPad Prism 6.

Results {#S3}
=======

Samples and *E. coli* Isolates {#S3.SS1}
------------------------------

We isolated 127 *E. coli* strains that included 108 (85.0%) urine and 5 (3.9%) uterus, 4 (3.1%) abdominal fluid, 3 (2.4%) pyoderma, 2 (1.6%) soft tissue infectious sites, and 1 (0.8%) from synovial fluid. The *E. coli* isolation rate was 6.73% (127/1886) and ranged from 4.42 to 9.41% per year. Resistance to β-lactams was extremely high for these isolates and included resistance to ampicillin (77.9%), cefotaxime (58.3%) and ceftriaxone (58.3%) and cefazolin (65.35%) with the exception of amoxicillin + clavulanic acid (22.8%) ([Supplementary Tables S2](#TS1){ref-type="supplementary-material"}, [S3](#TS1){ref-type="supplementary-material"}).

The range of resistance rates was narrow for ampicillin (68.42--92.86%) compared with cefotaxime (36.67--72.73%), ceftriaxone and cefotaxime (36.67--72.73%), cefazolin (43.33--86.36%), and amoxicillin + clavulanic acid (10.00--27.27%). These data demonstrated a significant increase in resistance rates from 2012 to 2017 and the cefotaxime, ceftriaxone, cefazolin, and amoxicillin + clavulanic acid rates more than doubled ([Supplementary Figure S1](#TS1){ref-type="supplementary-material"} and [Supplementary Table S3](#TS1){ref-type="supplementary-material"}). The aztreonam resistance rate showed the greatest variability and was maximal in 2014 (71.43%) and minimal in 2012 (13.33%). We also found high rates of resistance to the four fluoroquinolones we tested (52.76--57.48%) except for 2013 (36.84%) ([Supplementary Table S3](#TS1){ref-type="supplementary-material"}). The other resistance groups we examined displayed irregular trends or slight increases over the 2012--2017 study period. Notably, almost all isolates showed high susceptibility to the "last-resort" antibiotics colistin, meropenem, and tigecycline and only 5 (3.94%) of our isolates were resistant to colistin and 3 (2.4%) to meropenem ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table S3](#TS1){ref-type="supplementary-material"}).

![Multidrug resistance rates of 127 isolates based on antimicrobial category from 2012 to 2017.](fmicb-10-02852-g001){#F1}

The MDR values for our isolates from these pets were high with an overall MDR rate that increased 73.2% from 2012 to 2017 (*n* = 93). These MDR rates from 2012 to 2017 were 66.67, 68.42, 64.29, 85.71, 81.82, and 75.00% in 2017, respectively (*P* \< 0.0001) ([Supplementary Table S4](#TS1){ref-type="supplementary-material"}). Specifically, MDR prevalence in 6--9 antimicrobial categories exhibited an obvious increase ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table S4](#TS1){ref-type="supplementary-material"}). The MDR of our 44 CTX-M-producing *E. coli* was greater than for the non-CTX-M-expressing isolates ([Supplementary Figures S5a,b](#TS1){ref-type="supplementary-material"}). Moreover, all *bla*~CTX--M~-positive *E. coli* were MDR strains possessing resistance to the penicillins \[ampicillin (AMP)\], non-extended spectrum cephalosporins \[cefazoline (CZO)\], extended-spectrum cephalosporins \[cefotaxime (CTX) and ceftriaxone (CRO)\]. The most common MDR pattern was resistance to quinolones (ciproxacin, enrofloxacin, orbifloxacin, and marbofloxacin) and the tetracyclines (doxycycline) and aminoglycosides (gentamycin) + β-lactams (AMP, CZO, CTX, and CRO). When this data was viewed solely by the number of antibiotics per MDR isolate, resistance rates to 11--17 antibiotics increased significantly over the study period from 13.3, 31.6, 35.7, 35.7, 50.0, and 53.6% from 2012 to 2017, respectively ([Supplementary Figure S2](#TS1){ref-type="supplementary-material"} and [Supplementary Table S5](#TS1){ref-type="supplementary-material"}).

We performed a correlation analysis between antibiotic usage and the rate of antibiotic resistance between 2014 and 2017. Amoxicillin-clavulanic acid (1.3 × 10^7^ mg/yr), doxycycline (5.7 × 10^6^ mg/yr), ampicillin (1.9 × 10^6^ mg/yr), and enrofloxacin (8.1 × 10^5^ mg/yr) were the most widely used antibiotics at the animal facility. With the widespread use of FQs in VTH-CAU, \>50% of the clinical *E. coli* isolates showed resistance to FQs since 2012. Interestingly, even though fluoroquinolone usage had decreased dramatically, resistance rates to this antibiotic class remained high. In addition, the use of β-lactams, including amoxicillin-clavulanic acid, ampicillin, and ceftriaxone, had increased over the study period and was positively correlated with an increase in β-lactam resistance that was also related to dosage. Meropenem and imipenem were not used at the facility and we found no resistance from 2012∼2015 although three resistant *E. coli* were detected in 2016 ([Supplementary Figure S3](#TS1){ref-type="supplementary-material"}).

ARG Prevalence and NDM Plasmid Characterization {#S3.SS2}
-----------------------------------------------

In our study, we identified 10 ARG types and mutations in *gyrA* and *parC*. The *qnrB* gene was present in 119 (93.70%) of the isolates ([Supplementary Figure S4](#TS1){ref-type="supplementary-material"}). In the *gyr*A gene of 77 quinolone-resistant isolates, 38 carried the mutations S83L and D87N, 9 S83L and D87Y, 2 D87N, 3 D87G, and 14 S83L ([Supplementary Table S6](#TS1){ref-type="supplementary-material"}). In the *par*C gene we found the mutations S80I (22 isolates), S80I and E84G (14 isolates) and S80I and E84V (8 strains). The ESBL and pAmpC-containing isolates harbored *bla*~CTX--M~ (*n* = 44, 34.65%), *bla*~SHV~ (*n* = 21, 16.55%), *bla*~OXA~ (*n* = 9, 7.09%), *bla*~CMY~ (*n* = 12, 9.45%), *bla*~FOX~ (*n* = 4, 3.15%), and *bla*~NDM~ (*n* = 3, 2.36%). CTX-M alleles were assigned to two main clusters; CTX-M-14 and -15 including seven CTX-M genotypes (-14, -15, -64, -65, -116, -127, and -174) where CTX-M-65 (43.18%, *n* = 19) and CTX-M-5 (40.91%, *n* = 18) predominated. All 44 *bla*~CTX--M~-positive isolates were resistant to cefotaxime and ceftriaxone and were classified as MDR. When compared with *bla*~CTX~-negative isolates, the *bla*~CTX~-positive isolates showed significantly greater resistance to second and third-generation cephalosporins, the fluoroquinolones, aztreonam, doxycycline, gentamicin, and chloramphenicol (*P* \< 0.05) ([Table 1](#T1){ref-type="table"} and [Supplementary Figure S5](#TS1){ref-type="supplementary-material"}). The only observed carbapenemase gene we identified was NDM-5 that was present in three isolates 16DU02, 16DF03, and 16XXI8 and all showed resistance to meropenem and all were collected from dogs in 2016. Of note, 16DU02 and 16DF03 were isolated from same dog but the samples were isolated from urine and an abdominal effusion, respectively, and they carried same genes *bla*~NDM--5~, *bla*~TEM~, *bla*~CTX--M--65~, and *qnrB*. The 16XXI8 isolate recovered from dog urine possessed *bla*~NDM--5~, *bla*~TEM~, *bla*~CTX--M--15~, *bla*~OXA~, and *qnrB*. Additionally, the colistin resistance gene *mcr-1* was detected in three *bla*~CTX--M~ positive *E. coli* while other *mcr* variants were undetected.

###### 

Minimum inhibitory concentration (MIC) of antimicrobial agents for clinical *E. coli* isolates from cats and dogs in Beijing, China, 2012--2017 (*n* = 127)^‡^.

  **Antimicrobial agents**      ***bla***~**CTX**~***Positive E. coli* (*n* = 44)**   ***bla***~**CTX**~**Negative *E. coli* (*n* = 83)**   ***P*-value~†~**                            
  ----------------------------- ----------------------------------------------------- ----------------------------------------------------- ------------------ -------- -------- ------ ---------------
  Ampicillin                    \>128                                                 \>128                                                 100.0              \>128    \>128    63.8   \< 0.0001^∗∗^
  Cefazolin                     \>128                                                 \>128                                                 100.0              8        \>128    47.0   \< 0.0001^∗∗^
  Cefotaxime                    \>128                                                 \>128                                                 100.0              ≤0.125   \>128    31.3   \< 0.0001^∗∗^
  Ceftriaxone                   \>128                                                 \>128                                                 100.0              ≤0.125   \>128    31.3   \< 0.0001^∗∗^
  Meropenem                     ≤0.125                                                ≤0.125                                                6.8                ≤0.125   ≤0.125   0.0    0.0397^∗^
  Amoxicillin-clavulanic acid   16/8                                                  64/32                                                 27.3               16/8     32/16    14.4   0.0972
  Aztreonam                     32                                                    \>128                                                 75.0               ≤0.125   \>128    28.9   \< 0.0001^∗∗^
  Colistin                      ≤0.125                                                ≤0.125                                                6.8                ≤0.125   ≤0.125   1.2    0.1195
  Doxycycline                   16                                                    32                                                    59.1               8        32       32.5   0.0048^∗∗^
  Tigecycline                   ≤0.125                                                ≤0.125                                                0.0                ≤0.125   ≤0.125   0.0    1.0000
  Gentamycin                    \>128                                                 \>128                                                 77.3               8        \>128    36.1   \< 0.0001^∗∗^
  Amikacin                      8                                                     \>128                                                 27.3               8        \>128    13.2   0.0575
  Chloramphenicol               16                                                    \>128                                                 50.0               8        128      24.1   0.0052^∗^
  Ciprofloxacin                 16                                                    \>128                                                 81.8               0.25     64       37.3   \< 0.0001^∗∗^
  Enrofloxacin                  32                                                    128                                                   81.8               0.25     64       39.7   \< 0.0001^∗∗^
  Orbifloxacin                  128                                                   \>128                                                 81.8               4        \>128    38.6   \< 0.0001^∗∗^
  Marbofloxacin                 16                                                    64                                                    81.8               0.5      32       37.3   \< 0.0001^∗∗^

‡

The 127 isolates consisted of 107 isolates from urinary tract, 5 from uterus, 4 from abdominal fluid, 1 from synovial fluid, and 10 from pyoderma and soft tissue.

†

P-

values were determined by Fisher's exact test.

∗

P

\< 0.05;

∗∗

P

\< 0.01.

We further examined our *mcr-1* and *bla*~NDM~ isolates and tested whether these genes were present on mobile elements. In our conjugation tests, only *bla*~NDM~ in three *E. coli* isolates were successfully transferred at frequencies of 4.86 × 10^--8^--8.02 × 10^--7^. Two complete 46,161 bp *bla*~NDM--5~-harboring plasmids pP16NDM-502 (MN701974) and pP16NDM-503 (MN701975) were obtained from strains 16DU02 and 16DF03 transconjugants, respectively. The backbone sequences were assembled and contigs and gaps were identified by additional PCR and sequence analyses. The other NDM-1-carrying plasmid was unsuccessfully assembled because of fragmentary and short contigs ([Supplementary Figure S6](#TS1){ref-type="supplementary-material"}). The two completely assembled plasmids were all in the IncX3 replication group. In addition, *bla*~NDM--5~ was contained within an insertion sequence (IS) cassette (ΔISA*ba125*-IS*5*-*bla*~NDM~-*ble*-*trpF*-*dsbC*-IS*26*). *bla*~NDM--5~ and *ble*~MBL~ were the only ARGs present in the two plasmids. Homology analysis revealed that pP16NDM-502 and pP16NDM-503 were ≥ 99% identical to the following IncX3 *bla*~NDM~ plasmids: (i) pNDM_MGR194 (KF220657) from a *Klebisella pneumoniae* human isolate in India, (ii) p1079-NDM (MG825384) from a chicken *E. coli* isolate in China. (iii) pL65-9 (CP034744) from *E. coli* in goose in China, (iv) pZHDC40 (KY041843) from *E. coli* human isolate in China, (v) pQDE2-NDM (MH917280) from *K. pneumoniae* human isolate in China, (vi) pCRCB-101_1 (CP024820) from a *Citrobacter freundii* human isolate in Korea (vii) p128379-NDM (MF344560) from *Enterobacter hormaechei* from a human sample in China and (viii) pAD-19R (KX833071) from a chicken *E. coli* isolate in China ([Supplementary Figure S6](#TS1){ref-type="supplementary-material"}). We were unable to transfer the *mcr*-1 gene by conjugation in three separate tests and we could not assemble a complete plasmid sequence. However, no complete plasmid sequence of *mcr-1* was successfully assembled by using three clinical isolates genomes. Although the analysis of incompatibility group in three clinical isolates genomes by analyzed PlasmidFinder-2.0 Serve revealed they possessed IncFIB, IncFIC, IncFII, and IncHI2 typical fragments, all *mcr-1* genes weren't located on those fragments (data not showed).

PFGE and MLST Typing {#S3.SS3}
--------------------

In our group of 127 *E. coli* isolates, most (*n* = 109, 85.8%) were successfully characterized by PFGE typing and included 38/44 *bla*~CTX--M~-positive isolates. These 38 isolates were obtained from cats (6) and dogs (32) and could be subdivided into 36 unique PFGE patterns. Interestingly, two isolates obtained from urine (15cu184) and perirenal effusion (15cu186) samples showed identical PFGE patterns and carried the same *bla*~CTX--M--127~ subtype but were recovered from different animals ([Figure 2](#F2){ref-type="fig"}).

![*Xba*I pulsed-field gel electrophoresis (PFGE) analysis of *E. coli* containing *bla*~CTX~ variants.](fmicb-10-02852-g002){#F2}

We also found universality in MLST types and identified 28 different STs although 1 isolate failed to type. The most prevalent were ST405 (7, 15.9%), ST131 (3, 6.8%) ST73, ST101, ST372, and ST827 (2, 4.5% each). All ST405 strains were collected from dogs but in different years. Three ST131 isolates (UTI-27, UTI-166, and DU40) belonged to clade C1, in which UTI-27 and DU40 were assigned as C1-nM27, and UTI-166 as C1-M27. The *bla*~CTX--M--65~ and *bla*~CTX--M--15~ positive *E. coli* exhibited the greatest ST diversity and contained 13 and 14 STs, respectively. Additionally, three *bla*~NDM--5~-positive isolates belonged to ST405 (*n* = 1) and ST101 (*n* = 2) and three carrying-*mcr-1 E. coli* were classified as three different STs: ST6316, ST405, and ST46 ([Figure 3](#F3){ref-type="fig"}).

![*bla*~CTX--M~-positive *E. coli* MLST typing. **(A)** MLST type colored based on different years. **(B)** MLST type colored based on different origins.](fmicb-10-02852-g003){#F3}

Discussion {#S4}
==========

In this study, we investigated the antibiotic resistance profiles and trends in MDR *E. coli* isolates collected from diseased dogs and cats. We identified 127 *E. coli* isolates and most were associated with UTI (84.2%) accounting for 20.4% (108/529) of the confirmed bacterial UTI cases. In contrast, in the United States nearly 30% of UTI isolates from pets were *E. coli* ([@B35]; [@B23]). Previous studies in European countries based on 22,256 isolates from dogs and cats with UTI between 2008 and 2013 showed that *E. coli* was the most common pathogen in both dogs (59.50%) and cats (59.31%) ([@B43]). Isolation of *E. coli* from the respiratory tract is much less frequent and occurred in 10--15% of dog respiratory tract infections ([@B62]; [@B49]).

Our 127 clinical *E. coli* isolates showed high prevalence rates of resistance to β-lactams (58.3--77.9%) and quinolones (52.8--57.4%). This pattern was quite different from the data of dog and cat *E. coli* isolates from United States that identified resistance to ampicillin at 40%, cephalexin 98% and doxycycline at 100% ([@B73]). An Australian study revealed that canine clinical *E. coli* isolates had low rates of resistance to quinolones (9.1--9.3%) and among 392 canine UTI isolates, 9.9--10.2% were resistant to third-generation cephalosporins ([@B68]).

In the current study, the overall MDR frequency of 73.2% was higher than that observed in studies from the United States (52%) and Poland (66.8%) ([@B65]; [@B73]). In contrast, a European multi-centre study on AMR of various bacteria isolated from companion animals with UTIs showed a much lower frequency of MDR among *E. coli* isolates (1.4--29.7%). The high MDR rates observed in the current study indicated that currently available antimicrobial treatment options for *E. coli* infections in companion animals are limited. We also identified an increase in *E. coli* MDR prevalence between 2012 and 2017 and increased rates of third-generation cephalosporins and amoxicillin-clavulanic acid usage was accompanied by increased AMR and MDR rates. Based on these findings, we speculate that the rising incidence of multidrug-resistant *E. coli* might be associated with the heavy use of these antibiotics in companion animals at the hospital.

Among the 44 CTX-M-producing *E. coli* isolates in this study, *bla*~CTX--M--65~ (43.2%) and *bla*~CTX--M--15~ (40.9%) were the most *bla*~CTX--M~ variants. Currently, more than 220 CTX-M-lactamases have been reported and clustered into five subgroups, containing CTX-M-1, -2, -8, -9, and -25 depending on amino acid sequence homology ([@B54]). CTX-M-15 (CTX-M-1) is the most frequent CTX-M variant worldwide ([@B27]) especially in South-East Asia, China, South Korea, and Japan ([@B54]). Since 2000, *bla*~CTX--M--15~ has emerged worldwide and is the most prevalent ESBL globally ([@B54]). The spread of *bla*~CTX--M--15~ contributed to the dissemination of MDR bacterial isolates in animals but also in humans; a significant public health concern ([@B51]; [@B11]; [@B37]). While the *bla*~CTX--M--15~ variant was also common in canine *E. coli* isolates from both Shanxi, China (*n* = 40) and the United States (*n* = 50), *bla*~CTX--M--123~ predominated in those studies ([@B36], [@B37]). The *bla*~CTX--M--65~ was the most prevalent subtype we found and is frequently detected in *Salmonella* isolates. In a previous study, the *bla*~CTX--M--65~ gene (*n* = 131) was identified among 153 ESBL-positive *Salmonella* isolates from poultry slaughterhouses (*n* = 121) and humans (*n* = 10) ([@B6]). Similarly, a study on chickens and pigs in China surveyed seven *bla*~CTX--M--65~ among *Salmonella* isolates ([@B85]). All these studies indicated more frequent occurrences in China and is supported by data from 2005 to 2017 in another study ([@B8]). Additionally, *bla*~CTX--M--55~ prevalence has increased in recent years in China among animal and human isolates, although not in our present study. Conversely, *bla*~CTX--M--14~ has a remarkable reduction based on data for China ([@B8]). We found only one *bla*~CTX--M--14~ isolate while this gene is globally present ([@B8]). Although other *bla*~CTX--M~ variants, such as *bla*~CTX-M-64~, ~-174~, ~-116~, and ~-127~ rarely occur, their presence in diseased pets suggests that diversity and evolution of *bla*~CTX--M~ had occurred in these companion animals.

All *bla*~CTX~-carrying isolates in the current study had MDR profiles and showed high resistance rates to β-lactams, quinolones, doxycycline, gentamycin, and chloramphenicol. This suggested that other resistance genes may be co-transferred with *bla*~CTX~, making it even more difficult to eliminate the spread of MDR. Most *bla*~CTX--M~ positive strains in other studies were also resistant to quinolones due to topoisomerase modifications of *qnr* genes ([@B33]) as we found in the present study. Additionally, mutations in *gyrA* and *parC* also can be responsible for quinolone resistance. Our results showed S83L and D87 alterations to N, Y, G generated in *gyrA* were commonly associated with resistance to fluoroquinolones and mostly generate high level resistance ([@B7]).

Only three *E. coli* isolates containing *bla*~NDM--5~ were identified in our study animals with UTI in late 2016. Five (3.94%) were colistin resistance and three carried *mcr-1*. Previous reports implied that the transmissible *bla*~NDM~ and *mcr-1*-carrying plasmids play a major role in the dissemination of these genes ([@B79]). For example, *mcr-1*, initially named as mobile colistin resistance gene, was generally considered as mediating the rapid spread of bacterial colistin resistance worldwide due to its mobile plasmid association. In contrast, we found that *mcr-1* could not be mobilized by conjugation. In a previous study, 14/23 *mcr-1*-positive isolates were successfully transferred and six plasmids were non-transferable ([@B86]). The *mcr-1* gene was located in the chromosome of *E. coli* from a goose isolate ([@B40]). Furthermore, IS*Apl1* transposon can mediate *mcr-1* transfer from chromosome to plasmids and this is the reason for its current global distribution ([@B76]). So, *mcr-1*-carried in a non-transferable plasmid or chromosome may be spread by IS*Apl1* or others transposons. In our study, we could not assemble a complete plasmid sequence for the *mcr-1* genomic data; and *mcr-1* genes were not present on those plasmid fragments and may be chromosomal. There are nine variants of *mcr* and we identified only *mcr-1* ([@B12]). This gene is the most prevalent variant globally and has been detected in almost 40 countries/regions across five continents in both involving developed and non-developed countries. Moreover, the *mcr-1* gene was found in more than 11 bacterial species and in diverse locations such as rivers, public beaches, well water, wastewater, hospital sewage, foods (vegetables and meats), animals (wild birds, housefly/blowfly, cattle, pigs, poultry, and companion animals) ([@B19]). Our study provided new evidence for the above claim and we identified three *mcr-1* positive *E. coli* in diseased pets. Recently, carbapenem-resistant Enterobacteriaceae (CRE) have posed a threat to humans and animals because they exhibited resistance to most β-lactams including carbapenems, further compromising treatment of MDR infections ([@B22]; [@B59]).

Carbapenem-resistant Enterobacteriaceae is mediated largely by the production of carbapenemase especially for NDM isolates. NDM-5, an NDM-1 variant, exhibited increased enzyme activity to carbapenems ([@B63]) and its gene *bla*~NDM--5~ has been reported worldwide ([@B29]) and is the most prevalent variant in China ([@B69]). In support of this, 84 (52%) NDM-5-producing *E. coli* were collected from 161 *bla*~NDM~ carrying CRE in chickens ([@B79]). Our study revealed that pets have become a reservoir of NDM-5-producing *E. coli*. The *bla*~NDM--5~ gene is also associated with different plasmids such as IncFIA/B, IncFII, IncN, and IncX3 ([@B71]; [@B74]; [@B84]) and IncX3 was the dominant type ([@B34]; [@B84]). Similarly, the *bla*~NDM--5~-harboring plasmid was assigned to the IncX3 type, and their transferability was confirmed in our study indicating a risk of *bla*~NDM--5~ plasmid transfer between bacteria. However, further studies should be conducted to determine the origins of *bla*~NDM~ and *mcr-1* in the *E. coli* isolates from companion animals at the hospital. This will be helpful in designing measures to control the spread of MDR isolates.

All CTX-M-producing *E. coli* in our study displayed a diversity of PFGE patterns and STs demonstrating that *bla*~CTX--M~ encoding ESBLs are present in diverse *E. coli*. Additionally, our diseased pet samples were from animals having no prior contact suggesting that clonal spread had a low frequency and it was not likely that clonal spread of *bla*~CTX--M~-positive *E. coli* occurred between the pets. But ESBL or other resistance genes can transfer between different *E. coli* by transferable genetic elements, as previously reported ([@B30]). However, two *E. coli* isolates (15cu184 and 15cu186) from same cat but different sample sources shared the same PFGE, ST, and *bla*~CTX--M--127~ types, indicating that clonal spread may be occurring. It was reported that dissemination of Enterobacteriaceae can occur between pets and their owners by both horizontal transfer and clonal expansion ([@B83]).

In our study, ST405 *E. coli* (*n* = 7) was the most prevalent isolates carrying *bla*~CTX--M~. They presented different *bla*~CTX--M~ subtype genes including *bla*~CTX--M--15~ (*n* = 3), *bla*~CTX--M--65~ (*n* = 3), and *bla*~CTX--M--64~ (*n* = 1). In a clinical study from King Abdulaziz Medical City (KAMC) in Riyadh ([@B1]), six ST405 *E. coli* harboring *bla*~CTX--M~ were detected in UTI and ST405 (*P* ≤ 0.02) were significantly associated with ESBL production. ST405 extended-spectrum β-lactamase-producing *E. coli* (ESBL-EC) was also detected in animals, in which one ST405 ESBL-EC was screened in barbary macaques (*Macaca sylvanus*) in Algeria, notably, it held the *mcr-1*, *bla*~TEM--1~, and *qnrB19* genes and *bla*~CTX--M--15~ ([@B5]). We observed a similar pattern and a UTI25 (ST405 ESBL-EC) isolate harbored *mcr-1*, *bla*~TEM~, *qnrB*, and *bla*~CTX--M--64~. Additionally, ST405 ESBL-EC (16XXI8) carried *bla*~NDM--5~, *bla*~OXA~, *bla*~TEM~, and *qnrB*. These data indicated ST405 ESBL-EC has become the vector of multiple resistance genes, containing carbapenem- and colistin-resistance genes. In a Sweden project, ST405 ESBL-EC was also found in UTI from a diseased cat ([@B9]). We found seven ST405 ESBL-EC that were all recovered from dogs but in different years. Thus, companion animals already contain the hosts of ST405 ESBL-EC. In addition, except for ST405, we also identified two ST101 *E. coli* carrying *bla*~NDM--5~ (16DU02 and 16DF03). They were from the same animal source and possessed the same ST, PFGE, plasmid type and *bla*~NDM--5~, suggesting a clonal origin. ST101 was reported to be strongly associated with the NDM genotype although most were NDM-1 rather than NDM-5. Recently, five *bla*~NDM--5~-positive *E. coli* were identified associated with ST101 and ST1196 ([@B60]; [@B4]). In contrast, only two ST101 NDM-5-producing *E. coli* were observed in another study and most were ST167 and ST410 but were clonally spread in a hospital ([@B70]). This was similar to our study and suggested that ST101 may be becoming the most important clone for dissemination of *bla*~NDM--5~, similar to ST167 and ST410.

The clone ST131 was observed in three *E. coli* isolates. This is the predominant *E. coli* lineage in extraintestinal pathogenic *E. coli* (ExPEC) isolates worldwide and are associated with global community and nosocomial dissemination ([@B42]). Currently, ST131 is classified as three clades: A, B, and C ([@B54]). In our study, all ST131 belonged to clade C and ST131 is in clade C 80% of the time ([@B54]). Clade C evolved from clade B and further evolved into C1 and C2. Recently, a new C1 subclade C1-M27 was identified in animal and human ([@B45]), including companion animals ([@B47]), and we found one C1-M27 subclades that are rare in China, but prevalent in Europe ([@B20]; [@B48]). The other ST131 belonged to subclade C1-nM27. C1 is commonly associated with quinolone resistance, in agreement with our results. The ESBL-EC isolates were commonly associated with ST131, where 40--80% of ESBL ExPEC belong to ST131 *E. coli* ([@B42]), and CTX-15 was the most prevalent ESBL enzyme in ST131 ESBL-EC ([@B1]). Our study demonstrated that *bla*~CTX--M--65~ was found in two ST131 ESBL-EC and one *bla*~CTX--M--15~ isolate. Almost all ST131 isolates were resistant to fluoroquinolones, especially for ESBL CTX-M-15 isolates ([@B42]). We found similar results that almost all CTX-M ESBL isolates (40/44) were resistant to quinolones. ST131 ESBL *E. coli* possessed more frequent resistance to amikacin than non-ST131 ESBL isolates, but showed more frequent susceptibility to gentamicin or trimoxazole. On the other hand, the non-ESBL isolates such as *E. coli* ST131 were more frequently resistant to fluoroquinolones than non-ST131 isolates. Therefore, the resistance to quinolones may be associated with ST131 rather than ESBL presence ([@B42]). These findings indicated that quinolones resistance may have been the predecessor of ESBL enzymes. We found that ST131 and ST405 were correlated to ESBL production as previously found ([@B1]). Other STs in our study occurred infrequently. Recently, a water sample study revealed that ESBL-producing *E. coli* isolates were present 15 different STs (ST10, ST46, ST48, ST58, ST69, ST101, ST117, ST131, ST141, ST288, ST359, ST399, ST405, ST617, and ST4530) ([@B66]), We detected ST46, ST101, ST131, ST359, and ST405 in our study. Multiple ST types (ST46, ST1286, ST10, ST29, ST101, and ST354) have also been found in chickens and they carried *mcr-1* and produced ESBLs ([@B80]). In our work, 28 diverse STs in ESBL-EC were found.

Conclusion {#S5}
==========

We found a high prevalence of MDR *E. coli* isolates from diseased cats and dogs in Beijing and this rate has markedly increased over the last 6 years. The widespread use of third-generation cephalosporins and amoxicillin-clavulanic acid at the veterinary teaching hospital has likely contributed to the increasing frequency of β-lactam resistance in these isolates. These strains carried *bla*~CTX~, *bla*~NDM--5~, and *mcr-1* and most possessed an MDR profile. Diversity analysis of the PFGE patterns and STs of these clinical *E. coli* isolates from different origins suggested that the dissemination of *bla*~CTX~ have broad reservoirs of *E. coli*. Future studies should be undertaken to identify the MDR transmission mechanisms and establish national standards for the rational use of antibiotics in companion animals.
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